Newborn Screening for Spinal Muscular Atrophy: A 2.5-Year Experience in Hyogo Prefecture, Japan
Genes · 2023
DOI: 10.3390/genes14122211 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Genes, 2023. Verfasst von Shoko Sonehara und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. Hauptthemen laut MEDLINE: Neonatal Screening, Muscular Atrophy, Spinal. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nihon Syoni Sensiniryo Kyogikai, Novartis (Japan), Nihon Shōni Sensiniryō Kyōgikai and Novartis, Japan.
Abstract (Originalsprache)
Newborn screening (NBS) for spinal muscular atrophy (SMA) is necessary, as favorable outcomes can be achieved by treatment with disease-modifying drugs in early infancy. Although SMA-NBS has been initiated in Japan, its clinical results have not been fully reported. We report the findings of the initial 2.5 years of a pilot SMA-NBS of approximately 16,000 infants conducted from February 2021 in Hyogo Prefecture, Japan. Clinical data of 17 infants who tested positive were retrospectively obtained from the NBS follow-up centers participating in this multicenter cohort observational study. Genetic testing revealed 14 false positives, and three infants were diagnosed with SMA. Case 1 had two copies of survival motor neuron (SMN) 2 and showed SMA-related symptoms at diagnosis. Case 2 was asymptomatic, with two copies of SMN2. Asymptomatic case 3 had four copies of SMN2 exon 7, including the SMN1/2 hybrid gene. Cases 1 and 2 were treated within 1 month and case 3 at 8 months. All the patients showed improved motor function scores and did not require respiratory support. The identification of infants with SMA via NBS and early treatment improved their motor and respiratory outcomes. Thus, implementation of SMA-NBS at a nationwide scale should be considered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.
- Hyogo Prefectural Kobe Children's Hospital, 1-6-7 Minatozimaminami-cho, Chuo-ku, Kobe 650-0047, Japan.
- Department of Pediatrics, Hyogo Medical University, 1-1 Mukogawa-cho, Nishinomiya 663-8501, Japan.
- Department of Pediatrics, Toyooka Public Hospital, 1094 Tobera, Toyooka 668-8501, Japan.
- Faculty of Rehabilitation, Kobe Gakuin University, 518 Arise, Ikawadani-cho, Nishi-ku, Kobe 651-2180, Japan.
- Research Initiative Center, Organization for Research Initiative and Promotion, Tottori University, 86 Nishi-cho, Yonago 683-8503, Japan.
ORCID-Profile: Hideki Shimomura, Yasuhiro Takeshima, Kandai Nozu, Hisahide Nishio, Hiroyuki Awano
Förderung
- Nihon Syoni Sensiniryo Kyogikai
- Novartis (Japan)
- Nihon Shōni Sensiniryō Kyōgikai and Novartis, Japan
Zitieren
APA
Sonehara, S., Bo, R., Nambu, Y., Iketani, K., Lee, T., Shimomura, H., Ueda, M., Takeshima, Y., Iijima, K., Nozu, K., Nishio, H., & Awano, H. (2023). Newborn Screening for Spinal Muscular Atrophy: A 2.5-Year Experience in Hyogo Prefecture, Japan. Genes. https://doi.org/10.3390/genes14122211
Vancouver
Sonehara S, Bo R, Nambu Y, Iketani K, Lee T, Shimomura H, et al. Newborn Screening for Spinal Muscular Atrophy: A 2.5-Year Experience in Hyogo Prefecture, Japan. Genes. 2023. doi:10.3390/genes14122211
BibTeX
@article{Sonehara2023,
author = {Sonehara, Shoko and Bo, Ryosuke and Nambu, Yoshinori and Iketani, Kiiko and Lee, Tomoko and Shimomura, Hideki and Ueda, Masaaki and Takeshima, Yasuhiro and Iijima, Kazumoto and Nozu, Kandai and Nishio, Hisahide and Awano, Hiroyuki},
title = {Newborn Screening for Spinal Muscular Atrophy: A 2.5-Year Experience in Hyogo Prefecture, Japan},
journal = {Genes},
year = {2023},
doi = {10.3390/genes14122211}
}
EUVIMED